Somalogic, Inc.

Somalogic, Inc., 1745 38Th St
Boulder, CO 80301

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $400K
First Award Date 01/01/04
Most Recent Award Date 09/01/05

Key Personnel

Last Name Name Awards Contact
Heilig Joseph S Heilig 1
Cheronis John C Cheronis 3 Message

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 02/28/07

DESCRIPTION (provided by applicant): Treatment of rheumatoid arthritis (RA) has improved dramatically with the advent of the biological DMARDs (etanercept, infliximab, adalimumab and anakinra) and additional interventions with the potential of substantially altering the prognosis of this disease are in advanced clinical development. Unfortunatel...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-03-13
Budget: 07/01/04 - 06/30/06

DESCRIPTION (provided by applicant): An axiom of clinical medicine, particularly in oncology, is that early diagnosis of disease allows for more effective therapy and better clinical outcomes for patients. A major goal of SomaLogic is to improve the quality of life for patients through individualized medicine based on the quantitative analysi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-105
Budget: 04/19/04 - 09/30/06

DESCRIPTION (provided by applicant): Early diagnosis of disease allows for more effective therapy and better clinical outcomes. In cancer, extensive effort has gone toward development of screening and diagnostic techniques for early detection of disease. Despite this effort, the probability of single-analyte assays providing the "silver bullet"...

Phase 1 SBIR

Agency: Department of Homeland Security
Topic: 2004
Budget: 01/01/04 - 12/31/04

Antibodies are the prototypical capture reagent for biological agents (proteins and pathogens). However, despite their advantages, antibodies also have significant disadvantages with respect to shelf life, production reproducibility and, less importantly, cost. Alternative receptor scaffolds, such as nucleic acid-based photoaptamers, offer simil...